Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 80 clinical trials
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)

The investigators hypothesize that long-term disease-free survival (DFS) in patients with JMML can be achieved with a treatment of busulfan (BU), cyclophosphamide (CY) and melphalan (L-PAM) followed by hematopoietic cell transplantation (HCT).

melphalan
monocytosis
cell transplantation
ejection fraction
busulfan
  • 4 views
  • 02 Jun, 2021
  • 1 location
Azacitidine and Homoharringtonine in JMML

Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic stem cell transplant (HSCT) remaining the standard of care for cure. Azacitidine and homoharringtonine

azacitidine
myeloid leukemia
refractory acute myeloid leukemia (aml)
  • 0 views
  • 25 Jan, 2021
  • 1 location
Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells

AML patients with de-novo or secondary disease with age greater than 18 years not eligible for stem cell transplantation for medical contraindications, lack of donor or lack of stem cells,are eligible. Leukemias other than AML and M3 FAB subtype will be excluded from the study. Immunosuppressive chemotherapy prior to NK …

  • 9 views
  • 07 Nov, 2020
  • 1 location
A Study of H3B-8800 in Participants With Myelodysplastic Syndromes Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia

-8800 in subset of participants with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML). The study consists of two parts, a dose escalation part

hydroxyurea
chronic myelomonocytic leukemia
blood transfusion
myelodysplastic syndromes
bone marrow procedure
  • 0 views
  • 23 Mar, 2021
  • 27 locations
Study of ASTX727 vs IV Decitabine in MDS CMML and AML

Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily5 in Cycle 1 followed by IV decitabine 20 mg/m^2 Daily5 in Cycle 2, or the converse order. After completion of …

conjugated bilirubin
chronic myelomonocytic leukemia
secondary myelodysplastic syndrome
anemia
direct bilirubin
  • 269 views
  • 27 Jan, 2021
  • 93 locations
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 or IDH2-mutant advanced hematologic malignancies who have received standard therapy

hematologic malignancy
IDH2
blast cells
  • 0 views
  • 13 Jun, 2021
  • 17 locations
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R or Chronic Myelomonocytic Leukemia-2 (CMML-2)

or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who have an indication for treatment with azacitidine in first-line setting and are not

stem cell transplantation
cmml-2
chronic myelomonocytic leukemia
cell transplantation
myelomonocytic leukemia
  • 5 views
  • 12 Jun, 2021
  • 119 locations
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS) Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (AML)

The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared with single-agent azacitidine. (An event is defined as death or transformation to AML in participants with MDS or CMML, whichever occurs first, and is defined as death in participants …

chronic myelomonocytic leukemia
myelodysplastic syndromes
pevonedistat
induction chemotherapy
myeloid leukemia
  • 341 views
  • 13 Jun, 2021
  • 320 locations
Study to Assess Safety Tolerability Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of AZD4573 in subjects with relapsed or refractory haematological malignancies.

renal function
richter syndrome
chronic myelomonocytic leukemia
hodgkin's disease
progressive disease
  • 98 views
  • 05 Jun, 2021
  • 22 locations
A Study Evaluating Safety and Tolerability and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

navitoclax is evaluated on the PK, safety, and tolerability of a single dose of celecoxib in participants with myeloproliferative neoplasm (MPN) or chronic myelomonocytic leukemia (CMML).

stem cell transplantation
myelofibrosis
chronic myelomonocytic leukemia
ruxolitinib
polycythemia
  • 1 views
  • 27 Jan, 2021
  • 23 locations